- Category: Pre-exposure Prophylaxis (PrEP)
- Published on Tuesday, 16 July 2013 00:00
- Written by Gregory Fowler
Researchers at the 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2013) this month in Kuala Lumpur provided further details from the Bangkok Tenofovir Study, which showed that tenofovir pre-exposure prophylaxis, or PrEP, reduced the risk of HIV infection among people who inject drugs.
[Michael Martin speaks at IAS 2013 press conference, Kuala Lumpur, July 3, 2013]
As described last month in The Lancet, the trial found that daily tenofovir (Viread) reduced the risk of HIV infection among injection drug users by 49% overall and by more than 70% among participants who took tenofovir via directly observed therapy. But the study could not determine whether PrEP worked by preventing infections due to needle-sharing or sex.
Michael Martin from the U.S. Centers for Disease Control and Prevention presented further data on adherence and drug levels in the Bangkok trial. He summarized the findings at a press conference prior to his late-breaker presentation.
K Choopanya, S Vanichseni, P Suntharasamai, M Martin, et al (Bangkok Tenofovir Study Group). The Bangkok Tenofovir Study, an HIV pre-exposure prophylaxis trial in Thailand: participant adherence and study results. 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention. Kuala Lumpur, June 30-July 3, 2013. Abstract WELBC05.